La Jolla IVF Now Provides Day-6 Embryo Transfer as Part of in Vitro Fertilization Procedure

Share Article

The San Diego-based fertility center recently updated its standard protocol to perform biopsies for preimplantation genetic diagnosis (PGD) at day 5 with great results.

La Jolla IVF - San Diego Fertility Center and Fertility Specialists

La Jolla IVF - San Diego Fertility Center and Fertility Specialists

This new research has provided the opportunity to advance our technologies and provide the best possible results for our patients.

A Price Paper candidate at The American Society of Reproductive Medicine’s 67th annual meeting in Orlando, Florida outlined research in favor of waiting to perform the PGD biopsy at day 5 instead of day 3. La Jolla IVF decided to perform day-5 biopsies with day-6 embryo transfers yielding excellent results in regard to implantation rates.

“We feel strongly about staying up to date with the state-of-the-art technologies and remain committed to contributing to reproductive research,” commented La Jolla IVF’s Consulting Laboratory Director, Barry Behr, Ph.D, HCLD. “This new research has provided the opportunity to advance our technologies and provide the best possible results for our patients,” he added.

PGD is a procedure performed on embryos before they are transferred for implantation. La Jolla IVF uses the cutting-edge technology of microarrays to perform PGD. This procedure allows the screening of all 23 pairs of chromosomes of a developing embryo, which significantly reduces the chances of chromosomal abnormalities for the resulting baby.

Currently, the common practice is to perform a biopsy on the embryo at day 3. On day 3 of development, the embryo is at the cleavage stage, with a total of 6-8 cells. During the biopsy, one cell is extracted and sent away for genetic diagnosis.

At day 5, the embryo has progressed to the blastocyst stage. This means it now contains many cells (approximately 100), and has formed a cystic cavity. It has undergone the first step of differentiation by separating into the trophectoderm, which becomes the placenta and the inner cell mass, which becomes the fetus. La Jolla IVF's new methodology is to biopsy only embryos that reach this critical stage, which has resulted in a marked improvement in implantation rates for patients. More cells are able to be safely and confidently removed from the non-fetal compartment, resulting in a safer and more robust procedure.

Additionally, research has shown that abnormalities seen in day-3 embryos have the ability to self-correct by day 5—in essence, these embryos could be “saved” by waiting.

La Jolla IVF took this significant research into great consideration, and has changed its embryo transfers after PGD to take place on day 6. Since this technology was initiated, the San Diego fertility center has yielded excellent results for patients.

For more details and research about the blastocyst transfer procedure, please refer to La Jolla IVF's website.

About La Jolla IVF

Founded by David B. Smotrich, M.D., F.A.C.O.G., La Jolla IVF is a San Diego-based fertility center specializing in in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), blastocyst embryo transfer, surrogacy (including for single individuals and gay males), egg donation, PDG Micro Array technology, , gender selection, embryo freezing, egg freezing, sperm freezing and banking, and more. La Jolla IVF provides an award-winning facility and updates practices routinely to improve results for a wide variety of patients. La Jolla IVF welcomes all patients, regardless of marital status, ethnicity, or sexual orientation. To learn more, please visit. http://www.lajollaivf.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ruth MacAdam RN, CNM
Visit website